News and Media

Press Releases

2018

October 31, 2018
Casebia Therapeutics Expands Leadership Team with Addition of Dr. Adel Nada as Chief Medical Officer

May 30, 2018
Casebia Therapeutics Appoints Amy Jennings to Head its Regulatory Affairs

2017

November 13, 2017
CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs

September 27, 2017
Casebia Therapeutics Announces License and Collaboration Agreements with Seattle Children’s Research Institute

September 8, 2017
Casebia Therapeutics Strengthens Leadership Team with Two Key Appointments

June 28, 2017
Casebia Therapeutics names Robin A. Walker as Vice President, Head of Legal

May 11, 2017
Casebia Therapeutics Expands Leadership Team

March 14, 2017
CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement with MaxCyte

2016

November 1, 2016
Casebia Therapeutics Announces Appointment of James W. Burns, Ph.D. as President and Chief Executive Officer

In the News

2018

May 3, 2018
Evolving Industry Partnerships and Investments in Cell and Gene Therapies

2017

September 15, 2017
Boston Business Journal: Casebia Head of Legal Robin Walker named one of the 50 Most Influential People of Color in Healthcare & Life Sciences

Presentations and Abstracts

2019

ASGCT 2019  |  April 15, 2019
Abstract #135: Engineering Potent, Small, Chimeric, Synthetic, RNA-Guided Nucleases (sRGN) from Four Uncharacterized Cas9 Genes

ASGCT 2019  |  April 15, 2019
Abstract #428: Therapeutic Levels of FVIII Generated by CRISPR/Cas9-Mediated In Vivo Genome Editing in Hemophilia A Mice

ASGCT 2019  |  April 15, 2019
Abstract #494: Lipid Nanoparticle Formulations Optimized for Delivery and In Vivo Gene Editing Using Novel Synthetic RNA Guided Nucleases (sRGN)

ASGCT 2019  |  April 15, 2019
Abstract #550: CRISPR-Based Allele-Specific Editing for the Treatment of Autosomal Dominant Retinitis Pigmentosa (ADRP)

ASGCT 2019  |  April 15, 2019
Abstract #561: CRISPR Cas9/gRNAs Selective Targeting of the GUCY2D Mutant Allele for Autosomal Dominant Cone-Rod Retinal Dystrophy

ASGCT 2019  |  April 15, 2019
Abstract #660: Gene Editing to Enforce FOXP3 Expression and a Rapamycin-Inducible IL-2 Signaling Complex in Human Primary T Cells Allows Selective Expansion of Immunosuppressive Treg-Like Cells

ASGCT 2019  |  April 15, 2019
Abstract #839: Generation of Selectable, Multi-Edited Allogeneic CD3+ T Cells

ASGCT 2019  |  April 15, 2019
Abstract #850: Efficient and Sustained FOXP3 Locus Editing in Hematopoietic Stem Cells as a Therapeutic Approach for IPEX Syndrome

ASGCT 2019  |  April 15, 2019
Abstract #857: Manufacturing of Gene-Edited, Regulatory-Like, T Cells (edTreg) for Treatment of IPEX and Other Autoimmune Disorders

ASGCT 2019  |  April 15, 2019
Abstract #965: CRISPR/Cas9-Engineered Transgenesis of Hematopoietic Stem Cells via NHEJ-Mediated Targeted Integration Retains Engraftment Potential

Social Media

Alan Brooks from @CasebiaTx will be giving an oral presentation on our research around liver targeted insertion with LNP/AAV during #ASGCT19 to highlight our findings to date and the potential to treat #hemophiliaA in the future. Read more at https://t.co/hvAYXSU8Zo

New Cas-sRGN characterization in vitro studies research, a collaboration with @Bayer, that details overall improvements in specificity has been accepted for an oral presentation at #ASGCT19. Ashish Gupta of @Bayer will be presenting. View the abstract at https://t.co/vIviQQtRJe

See us on Twitter